- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2014 (2014), Article ID 258784, 9 pages
Network-Assisted Prediction of Potential Drugs for Addiction
1School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
2Department of Biomedical Informatics, Vanderbilt University School of Medicine, 2525 West End Avenue, Suite 600, Nashville, TN 37203, USA
3Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
4Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Received 22 November 2013; Accepted 30 December 2013; Published 9 February 2014
Academic Editor: Yufei Huang
Copyright © 2014 Jingchun Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. J. Kreek, “Drug addictions molecular and cellular endpoints,” Annals of the New York Academy of Sciences, vol. 937, pp. 27–49, 2001.
- J. C. Crabbe, “Genetic contributions to addiction,” Annual Review of Psychology, vol. 53, pp. 435–462, 2002.
- G. R. Uhl, “Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic process,” Neuropharmacology, vol. 47, supplement 1, pp. 140–147, 2004.
- C.-Y. Li, W.-Z. Zhou, P.-W. Zhang, C. Johnson, L. Wei, and G. R. Uhl, “Meta-analysis and genome-wide interpretation of genetic susceptibility to drug addiction,” BMC Genomics, vol. 12, article 508, 2011.
- A. J. Robison and E. J. Nestler, “Transcriptional and epigenetic mechanisms of addiction,” Nature Reviews Neuroscience, vol. 12, no. 11, pp. 623–637, 2011.
- A. I. Leshner, “Science-based views of drug addiction and its treatment,” Journal of the American Medical Association, vol. 282, no. 14, pp. 1314–1316, 1999.
- J. Knowles and G. Gromo, “A guide to drug discovery: target selection in drug discovery,” Nature Reviews Drug Discovery, vol. 2, no. 1, pp. 63–69, 2003.
- C. Knox, V. Law, T. Jewison et al., “DrugBank 3.0: a comprehensive resource for “Omics” research on drugs,” Nucleic Acids Research, vol. 39, no. 1, pp. D1035–D1041, 2011.
- J. Sun, Y. Wu, H. Xu, and Z. Zhao, “DTome: a web-based tool for drug-target interactome construction,” BMC Bioinformatics, vol. 13, supplement 9, 2012.
- H. Li, Z. Gao, L. Kang et al., “TarFisDock: a web server for identifying drug targets with docking approach,” Nucleic Acids Research, vol. 34, pp. W219–W224, 2006.
- A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008.
- D. K. Arrell and A. Terzic, “Network systems biology for drug discovery,” Clinical Pharmacology and Therapeutics, vol. 88, no. 1, pp. 120–125, 2010.
- J. Sun, H. Xu, and Z. Zhao, “Network-assisted investigation of antipsychotic drugs and their targets,” Chemistry Abd Biodiversity, vol. 9, pp. 900–910, 2012.
- J. Sun, M. Zhao, A. H. Fanous, and Z. Zhao, “Characterization of schizophrenia adverse drug interactions through a network approach and drug classification,” BioMed Research International, vol. 2013, Article ID 458989, 10 pages, 2013.
- R. Atreya, J. Sun, and Z. Zhao, “Exploring drug-target interaction networks of illicit drugs,” BMC Genomics, vol. 14, article S1, supplement 4, 2013.
- J. Wang, D. Duncan, Z. Shi, and B. Zhang, “WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013,” Nucleic Acids Research, vol. 41, pp. W77–W83, 2013.
- Y. Benjamini and Y. Hochberg, “Controlling the false discovery rate: a practical and powerful approach to multiple testing,” Journal of the Royal Statistical Society B, vol. 57, pp. 289–300, 1995.
- J. Xu, J. Sun, J. Chen, et al., “RNA-Seq analysis implicates dysregulation of the immune system in schizophrenia,” BMC Genomics, vol. 13, article S2, supplement 8, 2012.
- M. S. Cline, M. Smoot, E. Cerami et al., “Integration of biological networks and gene expression data using Cytoscape,” Nature protocols, vol. 2, no. 10, pp. 2366–2382, 2007.
- W.-C. Hwang, A. Zhang, and M. Ramanathan, “Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery,” Clinical Pharmacology and Therapeutics, vol. 84, no. 5, pp. 563–572, 2008.
- C. Boone, H. Bussey, and B. J. Andrews, “Exploring genetic interactions and networks with yeast,” Nature Reviews Genetics, vol. 8, no. 6, pp. 437–449, 2007.
- H. Yu, D. Greenbaum, H. X. Lu, X. Zhu, and M. Gerstein, “Genomic analysis of essentiality within protein networks,” Trends in Genetics, vol. 20, no. 6, pp. 227–231, 2004.
- Y. Assenov, F. Ramírez, S.-E. S.-E. Schelhorn, T. Lengauer, and M. Albrecht, “Computing topological parameters of biological networks,” Bioinformatics, vol. 24, no. 2, pp. 282–284, 2008.
- J. Sun, P. Jia, A. H. Fanous et al., “A multi-dimensional evidence-based candidate gene prioritization approach for complex diseases-schizophrenia as a case,” Bioinformatics, vol. 25, no. 19, pp. 2595–2602, 2009.
- A. Agrawal, K. J. Verweij, N. A. Gillespie, et al., “The genetics of addiction-a translational perspective,” Transl Psychiatry, vol. 2, Article ID e140, 2012.
- D. T. Mansie, “Abuse of temazepam capsules,” Australian Family Physician, vol. 24, no. 11, p. 2146, 1995.
- G. E. Ralston and J. A. Taylor, “Temazepam abuse,” Addiction, vol. 88, no. 3, p. 423, 1993.
- R. Hammersley, T. Lavelle, and A. Forsyth, “Buprenorphine and temazepam: abuse,” British Journal of Addiction, vol. 85, no. 2, pp. 301–303, 1990.
- M. S. Sakol, C. Stark, and R. Sykes, “Buprenorphine and temazepam abuse by drug takers in Glasgow: an increase,” British Journal of Addiction, vol. 84, no. 4, pp. 439–411, 1989.
- C. Stark, R. Sykes, and P. Mullin, “Temazepam abuse,” The Lancet, vol. 2, no. 8562, pp. 802–803, 1987.
- S. R. Calhoun, “Abuse potential of dronabinol (Marinol),” Journal of Psychoactive Drugs, vol. 30, no. 2, pp. 187–195, 1998.
- F. R. Levin, J. J. Mariani, D. J. Brooks, M. Pavlicova, W. Cheng, and E. V. Nunes, “Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial,” Drug and Alcohol Dependence, vol. 116, no. 1–3, pp. 142–150, 2011.
- M. J. Kreek, L. Borg, E. Ducat, and B. Ray, “Pharmacotherapy in the treatment of addiction: methadone,” Journal of Addictive Diseases, vol. 29, no. 2, pp. 209–216, 2010.
- P. A. M. Meulenbeek, “Addiction problems and methadone treatment,” Journal of Substance Abuse Treatment, vol. 19, no. 2, pp. 171–174, 2000.
- M. J. Cowley, M. Pinese, K. S. Kassahn, et al., “PINA v2. 0: mining interactome modules,” Nucleic Acids Research, vol. 40, pp. D862–D865, 2012.
- D. Emig, A. Ivliev, O. Pustovalova, et al., “Drug target prediction and repositioning using an integrated network-based approach,” PLoS ONE, vol. 8, Article ID e60618, 2013.
- Z. Wu, Y. Wang, and L. Chen, “Network-based drug repositioning,” Molecular BioSystems, vol. 9, pp. 1268–1281, 2013.
- T. Liu, Y. Lin, X. Wen, R. N. Jorissen, and M. K. Gilson, “BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities,” Nucleic Acids Research, vol. 35, no. 1, pp. D198–D201, 2007.
- F. Zhu, Z. Shi, C. Qin, et al., “Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery,” Nucleic Acids Research, vol. 40, pp. D1128–D1136, 2012.